Product Name :
FPL 62064
Description:
FLP 62064 is a potent 5-lipoxygenase (5-LOX) and COX-2 dual inhibitor. FLP 62064 has potently anti-inflammatory activity.
CAS:
103141-09-9
Molecular Weight:
265.31
Formula:
C16H15N3O
Chemical Name:
1H-Pyrazol-3-amine, N-(4-methoxyphenyl)-1-phenyl-
Smiles :
COC1C=CC(=CC=1)NC1C=CN(N=1)C1C=CC=CC=1
InChiKey:
WKLGNFJHVJIZPK-UHFFFAOYSA-N
InChi :
InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
FLP 62064 is a potent 5-lipoxygenase (5-LOX) and COX-2 dual inhibitor. FLP 62064 has potently anti-inflammatory activity.|Product information|CAS Number: 103141-09-9|Molecular Weight: 265.31|Formula: C16H15N3O|Chemical Name: 1H-Pyrazol-3-amine, N-(4-methoxyphenyl)-1-phenyl-|Smiles: COC1C=CC(=CC=1)NC1C=CN(N=1)C1C=CC=CC=1|InChiKey: WKLGNFJHVJIZPK-UHFFFAOYSA-N|InChi: InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (942.29 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|FPL 62064 inhibits both 5-1ipoxygenase (IC50 of 3.5 μM for RBL-1 cytosolic 5-1ipoxygenase) and prostaglandin synthetase (IC50 of 3.1 μM for seminal vesicle prostaglandin synthetase ) with equal facility in the isolated enzyme screens. However in the intact RBL-I cell prostaglandin synthetase (IC50 of 3.6 μM) is more readily inhibited by FPL 62064 than is 5-1ipoxygenase (IC50 of 31 μM).{{Mecillinam} MedChemExpress|{Mecillinam} Bacterial|{Mecillinam} Epigenetics|{Mecillinam} Purity & Documentation|{Mecillinam} Description|{Mecillinam} supplier} This difference in sensitivity is not reflected in the mouse macrophage where the IC50s for leukotriene (IC50 of 0.{{Protocatechuate 3,4-dioxygenase} medchemexpress|{Protocatechuate 3,4-dioxygenase} Protocol|{Protocatechuate 3,4-dioxygenase} References|{Protocatechuate 3,4-dioxygenase} manufacturer|{Protocatechuate 3,4-dioxygenase} Epigenetic Reader Domain} 72 μM) and prostaglandin (IC50 of 0.PMID:27102143 43 μM) production are similar.|In Vivo:|FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex.|References:|Blackham A, et al. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.Shabaan MA, et al. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase. Arch Pharm (Weinheim). 2020 Feb 7:e1900308.Products are for research use only. Not for human use.|
